Vaxcyte, Inc.
Vaxcyte (PCVX) shares fell 5.4% due to dilution concerns from a $1.15B financing round. The company raised funds via equity and convertible notes, with proceeds earmarked for clinical development and commercial prep. Insiders sold shares, while hedge funds showed mixed activity. Topline trial data is expected by late October 2026.
Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte (PCVX) with a $120.00 price target. The company has a $10.62B market cap, negative earnings, and a GF Score of 36/100. Insiders sold $6.32M in shares over three months. Analysts see growth potential in its vaccine candidates, but profitability and growth remain challenges.
Vaxcyte's EVP and COO Jim Wassil sold 18,000 shares for $1.56m at $86.74 each on Oct 5, 2026, and acquired 18,000 shares via option exercise. He now holds 145,435 shares. Vaxcyte's OPUS-1 trial succeeded, with analysts raising price targets to $125-$146. The stock is down to $71.38 but up 63% over a year.
Over the past 7 days, AlphAI's AI scored 17 news stories mentioning PCVX (Vaxcyte, Inc.). Coverage has been balanced: 7 bullish, 3 neutral, and 7 bearish.
Recent PCVX coverage spans financial news, market movers and corporate actions.
In the last 30 days, PCVX insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($3.3M). The most active reporter was Wassil Jim, EVP, Chief Scientific Ofc, COO, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The large financing likely creates dilution and supply pressure, pushing the stock lower.
Analyst upgrade with a higher price target may attract buying interest.
The insider sale may signal reduced confidence or portfolio rebalancing, potentially weighing on the stock.
The insider sale may signal confidence concerns and could weigh on the stock.
The large debt and equity raise introduces dilution and additional leverage, likely weighing on the stock in the short term.
AlphAI scores every news story that mentions PCVX with an AI model for sentiment and relevance, and aggregates insider trades from Vaxcyte, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vaxcyte (PCVX) shares fell 5.4% due to dilution concerns from a $1.15B financing round. The company raised funds via equity and convertible notes, with proceeds earmarked for clinical development and commercial prep. Insiders sold shares, while hedge funds showed mixed activity. Topline trial data is expected by late October 2026.
2 min readCantor Fitzgerald reiterated its Overweight rating for Vaxcyte (PCVX) with a $120.00 price target. The company has a $10.62B market cap, negative earnings, and a GF Score of 36/100. Insiders sold $6.32M in shares over three months. Analysts see growth potential in its vaccine candidates, but profitability and growth remain challenges.
2 min readVaxcyte's EVP and COO Jim Wassil sold 18,000 shares for $1.56m at $86.74 each on Oct 5, 2026, and acquired 18,000 shares via option exercise. He now holds 145,435 shares. Vaxcyte's OPUS-1 trial succeeded, with analysts raising price targets to $125-$146. The stock is down to $71.38 but up 63% over a year.
1 min readVaxcyte's SVP Elvia Cowan sold 19,000 shares for $1.65M, exercised options for 19,000 shares at $25.92 each, and now holds 27,860 shares. Vaxcyte's VAX-31 trial met its primary endpoint, leading to raised price targets from BofA ($130), Guggenheim ($125), and BTIG ($89). The stock is up 63% over the past year but is currently trading at $71.38.
1 min readVaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 9, 2026, Vaxcyte, Inc. (“ Vaxcyte ”) consummated the sale and issuance of $575,000,000 aggregate principal amount of its 1.50% Convertible Senior Notes due 2032 (the “ Notes ”) to certain underwriters (the “ Debt Of
2 min readA new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.
2 min readVaxcyte (PCVX) priced concurrent offerings: 7.4M shares at $64 each, pre-funded warrants for 400K shares at $64, and $500M convertible notes due 2032. Underwriters have 30-day over-allotment options. Latham & Watkins advised the underwriters.
1 min readVaxcyte (PCVX) reported positive Phase 3 data for its pneumococcal vaccine and raised $1b via equity and debt. Its shares rose 17.68% in 7 days, 44.12% YTD, and 64.36% in 1 year. Analysts' price targets average $114.78, while intrinsic value models suggest higher potential.
2 min readWassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares of Vaxcyte, Inc. (PCVX) at $86.74 ($1.56M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readCowan Elvia (SVP, Finance & CAO) sold 19,000 shares of Vaxcyte, Inc. (PCVX) at $86.74 ($1.65M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min read
